eurofeedback treatment of auditory verbal hallucinations

Not Applicable

Completed

• Conditions: Schizophrenia patients (ICD-10: F20 and/or F25) with auditory verbal hallucinations; Mental and Behavioural Disorders; Schizophrenia

• Registration Number: ISRCTN23930628
• Lead Sponsor: niversity Hospital of Psychiatry Bern (Switzerland)

Brief Summary

1. 2017 results in https://doi.org/10.1177%2F1550059417708935 (added 31/01/2019) 2. 2018 results in https://doi.org/10.1177%2F1550059418765810 (added 31/01/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-02-10
• Study Completion: 2016-06-30
• Last Update Posted: 11 February 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Male and female, age 18-45 years
2. ICD-10: in-patients of the University Hospital of Psychiatry in Bern with schizophrenia (F20) or schizoaffective disorder (F25) , prone to AVH in the acute phases of the disorder (the medication has to be stable during the training as defined in the exclusion criteria)
3. AVH in the present phase of disorder
4. Able to give written informed consent and to participate in 2 weeks of NFB training

Exclusion Criteria

1. Psychiatric or neurologic disease (except for ICD-10: F20/F25)
2. Hearing problems
3. Vision problems (uncorrected)
4. Substance abuse during the previous 2 weeks (except THC)
5. Change in medication (type and quantity) during the 2 weeks of training
6. Pregnancy and nursing mothers
7. Suicidal risk
8. Not capable of judgment or capacity to consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Individual difference in the post-pre (last-first session) comparison of the PsyRats-Auditory Hallucinations Subscale will be compared between treatment and placebo group. Comparison 1st vs. 20th session.

Secondary Outcome Measures

Name	Time	Method
<br> 1. The ability to modulate the N100 component (with feedback) within session, in the training against the placebo group. Every single session will be compared in both groups (session 1-20)<br> 2. A learning effect, i.e. an increase of modulation of the N100 across sessions, in the training against the placebo group will be calculated with a regression analysis. The training will take place over two weeks every day from Monday to Friday with 2 sessions a day<br> 3. A transfer effect, showing that participants in the training group can modulate the N100 component without feedback. Comparison 1st vs. 20th session.<br> 4. A change in the psychopathology of the positive symptoms, the subjective controllability and well being is assessed. After each session a questionnaire will be filled out (1-20 comparison).<br>